HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The myth of measurable disease in ovarian cancer: revisited.

Abstract
There are well-documented and serious limitations associated with analyzing measurable disease in ovarian cancer as a sole primary endpoint in clinical trials, as this focus requires the presence of individual tumor masses of sufficient size and distinctive shape to image. An alternative highly rational strategy adds the routine monitoring of validated serum tumor markers (e.g., CA-125), which can more adequately define changes in "tumor volume" associated with small nonvisualized macroscopic and diffuse microscopic cancer.
AuthorsMaurie Markman
JournalCancer investigation (Cancer Invest) Vol. 27 Issue 1 Pg. 11-2 (Jan 2009) ISSN: 1532-4192 [Electronic] England
PMID19160094 (Publication Type: Journal Article, Review)
Chemical References
  • Biomarkers, Tumor
  • CA-125 Antigen
Topics
  • Biomarkers, Tumor (blood)
  • CA-125 Antigen (blood)
  • Female
  • Humans
  • Ovarian Neoplasms (blood, diagnosis)
  • Predictive Value of Tests

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: